Wendy Erler started her career in the 90s with the pharmaceutical company, GlaxoSmithKline. It was around that time when the drug discovery and development industry began to swiftly change. The question of incorporating a patient’s voice into research became important. That’s where her passion for patient advocacy began. Today, she’s building frameworks and creating an environment that ensures patient’s insights positively influence corporate decision making surrounding their needs.
Wendy joined Alexion three years ago, and since has worked on a variety of programs to change behaviors internally to better deliver on the needs of patients. STAR (Solutions To Accelerate Results) is a program that encourages the streamlining of innovation, promotion of discussion, and collaboration between Alexion colleagues and stakeholders, and external patients and physicians of all backgrounds to develop solutions that have a greater impact on patient lives. Another program, Leap, inserts employees into a simulated experience of the patient journey; such as receiving a diagnosis and the process of preparing for and partaking in a clinical trial. This way, staff can understand the everyday situations people go through from the patient perspective.
Wendy is excited about the future n-of-1 treatment and points out the advantages of ASOs. She discusses that, opposed to other drug discovery platforms, ASOs can be easily altered with a clearer understanding of the expected results. Also, the time it takes to develop an ASO is quick in comparison to other drug options! n-Lorem is discovering quality ASOs for patients, making a difference, and building a community while doing it. Alexion is committed to helping patients with rare diseases and has generously supported n-Lorem’s mission of providing personalized experimental ASO medicines to treat nano-rare patients – for free, for life.